| Date Filed | Type | Description |
| 10/02/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 08/04/2023 |
S-3/A
| Form S-3/A - Registration statement under Securities Act of 1933: [Amend] |
| 08/04/2023 |
8-K
| Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits Interactive Data |
| 07/31/2023 |
10-K
| Annual Report for the period ended April 30, 2023 |
| 07/31/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 07/19/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 06/16/2023 |
SC 13D/A
| Iroquois Capital Management, LLC reports a 5% stake in PharmaCyte Biotech, Inc. |
| 06/09/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 05/25/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 05/19/2023 |
SC 13G
| Ayrton Capital LLC reports a 10% stake in PHARMACYTE BIOTECH INC. |
| 05/12/2023 |
SC 13D/A
| Iroquois Capital Management, LLC reports a 7% stake in PharmaCyte Biotech, Inc. |
| 05/11/2023 |
SC TO-I
| Form SC TO-I - Tender offer statement by Issuer: |
| 05/11/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation ... |
| 03/16/2023 |
10-Q
| Quarterly Report for the period ended January 31, 2023 |
| 02/08/2023 |
SC 13G/A
| INTRACOASTAL CAPITAL, LLC reports a 10% stake in PharmaCyte Biotech, Inc. |
| 02/02/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 01/10/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 12/30/2022 |
8-K
| Quarterly results |
| 12/14/2022 |
10-Q
| Quarterly Report for the period ended October 31, 2022 |
| 11/25/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 11/18/2022 |
8-K
| Quarterly results |
| 11/15/2022 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 11/07/2022 |
8-K
| Quarterly results |
| 10/20/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 10/14/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 10/07/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 09/14/2022 |
10-Q
| Quarterly Report for the period ended July 31, 2022 |
| 08/15/2022 |
8-K
| Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...|
Docs:
|
"Cooperation Agreement dated August 15, 2022, by and between PharmaCyte Biotech, Inc. and Iroquois Master Fund Ltd. and its affiliates",
"Form of Director Offer Letter",
"PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital; Company Appoints Five New Independent Directors to Reconstituted Board LAS VEGAS, NV, August 15, 2022 -- -- PharmaCyte Biotech, Inc. , a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that PharmaCyte and Iroquois Master Fund Ltd. and its affiliates, the beneficial owners of approximately 6.7% of PharmaCyte’ s outstanding shares of common stock, have signed a Cooperation Agreement that includes naming two of Iroquois’ director designees to PharmaCyte’ s reconstituted Board of Directors. Pursuant to the Agreement, Iroquois’ director designees, Jonathan L. Schechter and Joshua ..." |
|
| 08/15/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 08/15/2022 |
SC 13D/A
| Iroquois Capital Management, LLC reports a 6.7% stake in PharmaCyte Biotech, Inc. |
| 07/28/2022 |
10-K
| Annual Report for the period ended April 30, 2022 |
| 07/28/2022 |
8-K
| Quarterly results |
| 07/28/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 07/28/2022 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material: |
|